For research use only. Not for therapeutic Use.
Fusidic Acid（Cat No.:R007756）is a steroidal antibiotic commonly used in the treatment of bacterial infections, particularly those caused by Gram-positive organisms such as Staphylococcus aureus. It works by inhibiting bacterial protein synthesis by binding to elongation factor G (EF-G), preventing the translocation step in bacterial protein elongation. Fusidic acid is often used topically for skin infections, including impetigo, and in combination with other antibiotics for more serious systemic infections. Its bacteriostatic action makes it effective against resistant strains, including methicillin-resistant Staphylococcus aureus (MRSA).
| Catalog Number | R007756 |
| CAS Number | 6990-06-3 |
| Synonyms | (3α,4α,8α,9β,11α,13α,147β,167β,17Z)-16-(Acetyloxy)-3,11-dihydroxy-29-nordammara-17(20),24-dien-21-oic Acid; Flucidin; Fucithalmic; Fusidinic Acid; NSC 56192; Ramycin; SQ 16603; |
| Molecular Formula | C31H48O6 |
| Purity | ≥95% |
| Target | Bacterial |
| Storage | Store at -20°C |
| IUPAC Name | (2Z)-2-[(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid |
| InChI | InChI=1S/C31H48O6/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36)/b26-20-/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-/m0/s1 |
| InChIKey | IECPWNUMDGFDKC-MZJAQBGESA-N |
| SMILES | C[C@H]1[C@@H]2CC[C@]3([C@H]([C@]2(CC[C@H]1O)C)[C@@H](C[C@@H]\4[C@@]3(C[C@@H](/C4=C(/CCC=C(C)C)\C(=O)O)OC(=O)C)C)O)C |
| Reference | </br>1:Mechanisms of drug-drug interaction between rifampicin and fusidic acid. Bel F, Bourguignon L, Tod M, Ferry T, Goutelle S.Br J Clin Pharmacol. 2017 Apr 12. doi: 10.1111/bcp.13277. [Epub ahead of print] No abstract available. PMID: 28406539 </br>2:Quantitative analysis of binary polymorphs mixtures of fusidic acid by diffuse reflectance FTIR spectroscopy, diffuse reflectance FT-NIR spectroscopy, Raman spectroscopy and multivariate calibration. Guo C, Luo X, Zhou X, Shi B, Wang J, Zhao J, Zhang X.J Pharm Biomed Anal. 2017 Jun 5;140:130-136. doi: 10.1016/j.jpba.2017.02.053. Epub 2017 Mar 10. PMID: 28359962 </br>3:Severe Rhabdomyolysis as Complication of Interaction between Atorvastatin and Fusidic Acid in a Patient in Lifelong Antibiotic Prophylaxis: A Dangerous Combination. Nandy A, Gaïni S.Case Rep Med. 2016;2016:4705492. doi: 10.1155/2016/4705492. Epub 2016 Dec 27. PMID: 28115938 Free PMC Article</br>4:Synthesis and biological characterisation of ester and amide derivatives of fusidic acid as antiplasmodial agents. Espinoza-Moraga M, Singh K, Njoroge M, Kaur G, Okombo J, De Kock C, Smith PJ, Wittlin S, Chibale K.Bioorg Med Chem Lett. 2017 Feb 1;27(3):658-661. doi: 10.1016/j.bmcl.2016.11.077. Epub 2016 Nov 25. PMID: 28012840 </br>5:Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid. Marsot A, Ménard A, Dupouey J, Muziotti C, Guilhaumou R, Blin O.Br J Clin Pharmacol. 2017 May;83(5):1039-1047. doi: 10.1111/bcp.13178. Epub 2017 Jan 16. PMID: 27813241 </br>6:Where to from here? The treatment of impetigo in children as resistance to fusidic acid emerges. Vogel A, Lennon D, Best E, Leversha A.N Z Med J. 2016 Oct 14;129(1443):77-83. PMID: 27736855 </br>7:Increasing resistance to fusidic acid among clinical isolates of MRSA. Wang JT, Huang IW, Chang SC, Tan MC, Lai JF, Chen PY, Lauderdale TL.J Antimicrob Chemother. 2017 Feb;72(2):616-618. doi: 10.1093/jac/dkw430. Epub 2016 Oct 12. No abstract available. PMID: 27733516 </br>8:A Randomized Study Evaluating Oral Fusidic Acid (CEM-102) in Combination With Oral Rifampin Compared With Standard-of-Care Antibiotics for Treatment of Prosthetic Joint Infections: A Newly Identified Drug-Drug Interaction. Pushkin R, Iglesias-Ussel MD, Keedy K, MacLauchlin C, Mould DR, Berkowitz R, Kreuzer S, Darouiche R, Oldach D, Fernandes P.Clin Infect Dis. 2016 Dec 15;63(12):1599-1604. Epub 2016 Sep 28. PMID: 27682068 </br>9:Inhibition of Hepatobiliary Transport Activity by the Antibacterial Agent Fusidic Acid: Insights into Factors Contributing to Conjugated Hyperbilirubinemia/Cholestasis. Lapham K, Novak J, Marroquin LD, Swiss R, Qin S, Strock CJ, Scialis R, Aleo MD, Schroeter T, Eng H, Rodrigues AD, Kalgutkar AS.Chem Res Toxicol. 2016 Oct 4. [Epub ahead of print] PMID: 27676153 </br>10:Screening of drug metabolizing enzymes for fusidic acid and its interactions with isoform-selective substrates in vitro. Chen D, Lin XX, Zhao Q, Xiao J, Peng SF, Xiao MF, Ouyang DS, Tan ZR, Wang YC, Peng JB, Zhang W, Chen Y.Xenobiotica. 2016 Nov 15:1-7. doi: 10.1080/00498254.2016.1230795. [Epub ahead of print] PMID: 27571049 |
